John Sarantopoulos, MD

Dr. John Sarantopoulos is a clinical research investigator and medical oncologist, with a full-time faculty appointment as assistant professor of medicine in the division of hematology-oncology at The University of Texas Health Science Center San Antonio. His clinical interests and expertise are in early antineoplastic drug development and evaluation for human solid tumors including genitourinary malignancies of renal, prostate, bladder and melanoma. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, he is involved with the early therapeutics phase I program, and is a member of the experimental developmental therapeutics program.

Dr. Sarantopoulos completed an advanced drug development fellowship and is presently focusing on early phase I/II trials. He has been a co-principal investigator and principal investigator in over 54, phase I solid tumor studies, including first in human studies or first in class compounds, food effect or bioequivalence studies, drug interaction studies, QTc effect studies, and organ dysfunction studies, including renal and hepatic impairment. Studies have included National Cancer Institute cancer therapy evaluation program studies and the NCI organ dysfunction working group and cooperative group trials including the Southwest Oncology Group, where he is a member of the early therapeutics and genitourinary committees, as well as industry-sponsored and cancer center investigator-initiated trials.

In addition, he has been a sub-investigator in over 139 trials in this area at the Mays Cancer Center over the last several years. Dr. Sarantopoulos’ education, clinical and research experiences place him in a select group of investigators that can complete complex early phase trials that are important to the development of new treatments for patients with cancer.